banner
FGFR inhibitor Debio-1347, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ078

FGFR inhibitor Debio-1347, Purity ≥98%

Inquiry

Synonym: 1265229-25-1; FGFR inhibitor; Debio 1347; Debio1347; CH5183284; CH 5183284; CH-5183284; FF-284; FF284; FF 284

  • MDL: MFCD28502053
  • CAS Number: 1265229-25-1
  • Compound CID: 66555680
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg
Price
Datasheet
Datasheet
MSDS
MSDS
Properties
Description
Debio-1347, soluble in DMSO and warmed ethanol and insoluble in water, is a protein tyrosine kinase inhibitor that has shown potent biochemical activity against FGFR. It targets FGFR1, FGFR2, FGFR3, and FGFR4.
Molecular Weight
356.38
Molecular Formula
C20H16N6O
Targets
FGFR1: 9.3 nM; FGFR2: 7.6 nM; FGFR3: 22 nM; FGFR4: 290 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 70 mg/mL (196.41 mM); Water: Insoluble; Warmed ethanol: 1 mg/mL
Identity
Confirmed by NMR/HPLC/MS.
Applications
Debio-1347 is used to investigate and inhibit FGFR, contributing to cancer research, specifically targeting tumors with FGFR genetic alterations.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links
(CD BioGlyco)
Lipidomics Analysis Services
(CD BioGlyco)
Glycolipid Profiling
(CD BioGlyco)
HTS of Glycan Derivatives
PRODUCTS
Featured Products
Nucleic Acid Drug Delivery Products
GalNAc-L96 intermediate, T1 (Cat#: X24-11-YM010) GalNAc-L96 intermediate, T2 (Cat#: X24-11-YM011) GalNAc-L96 intermediate, T3 (Cat#: X24-11-YM012) GalNAc-L96 intermediate, T4-Amine (Cat#: X24-11-YM014) Tri-GalNAc(OAc)3 Cbz (Cat#: X24-11-YM015) Tri-GalNAc(OAc)3 (Cat#: X24-11-YM016) Tri-GalNAc(OAc)3 TFA (Cat#: X24-11-YM017) GalNAc-L96-OH (Cat#: X24-11-YM018) GalNAc-L96-TEA (Cat#: X24-11-YM019)
Hots Products
N-Glycan
Neu5Gcα(2-6)N-Glycan (Cat#: X23-03-YW036) A2G2 N-Glycan (Cat#: X23-03-YW037) A2G2S2 N-Glycan (Cat#: X23-03-YW038) A2 N-Glycan (Cat#: X23-03-YW039) A2[6]G1 N-Glycan (Cat#: X23-03-YW040) M3 N-Glycan (Cat#: X23-03-YW041) A2[3]G2S1 N-Glycan (Cat#: X23-03-YW042)
O-Glycan
Core 2 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW178) Core 2 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW179) Core 3 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW180) Core 3 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW181) Core 4 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW182) T antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW192) T antigen O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW193) Tn antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW194)
Blood Group and Lewis Antigen
Blood group A trisaccharide (Cat#: XCO0060Q) Blood group B trisaccharide (Cat#: XCO0068Q) Blood group H disaccharide (Cat#: XCO0074Q) Lewis A trisaccharide (Cat#: XCO0079Q) 3'-Sulfated lewis A (Cat#: XCO0080Q) Lewis B tetrasaccharide (Cat#: XCO0083Q) Lewis X trisaccharide (Cat#: XCO0085Q) Lewis Y tetrasaccharide (Cat#: XCO0088Q)
Human Milk Oligosaccharides (HMOs)
Lacto-N-biose (Cat#: XCO0089Q) 2'-Fucosyllactose (Cat#: XCO0091Q) 3-Fucosyllactose (Cat#: XCO0092Q) Lactodifucotetraose (Cat#: XCO0093Q) Lacto-N-triose I (Cat#: XCO0094Q) 3'-Sialyllactose sodium salt (Cat#: XCO0096Q) 6'-Sialyllactose sodium salt (Cat#: XCO0098Q) 3'-Sialyl-3-fucosyllactose (Cat#: XCO0100Q)
Glycosaminoglycans
Heparin amine, MW 27 kDa (Cat#: X22-09-ZQ478) FITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ480) TRITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ481) Biotin-heparin-FITC, MW 18 kDa (Cat#: X22-09-ZQ482) Chondroitin sulfate (dp4) (Cat#: X22-11-ZQ598) Dermatan sulfate (dp12) (Cat#: X22-11-ZQ611) Heparin disaccharide I-A (Cat#: X22-11-ZQ662) Chondroitine sulfate (Cat#: X23-04-XQ1118)
Carbohydrate Conjugates
GalNAcβ(1-4)GlcNAcβ-Sp3-Biotin (Cat#: X22-12-ZQ005) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-Biotin (Cat#: X22-12-ZQ006) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-FITC (Cat#: X22-12-ZQ007) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA (Cat#: X22-12-ZQ008) Glcβ(1-4)GalNAcα-Sp3-Biotin (Cat#: X22-12-ZQ037) Glcβ(1-4)GalNAcα-Sp3-PAA-Biotin (Cat#: X22-12-ZQ038) Glcβ(1-4)GalNAcα-Sp3-PAA-FITC (Cat#: X22-12-ZQ039) Glcβ(1-4)GalNAcα-Sp3-PAA (Cat#: X22-12-ZQ040)
Glycolipids
GlcCer (d18:1/8:0) (Cat#: X23-11-ZQ101) GalCer (d18:1/16:0) (Cat#: X23-11-ZQ112) LacCer (d18:1/8:0) (Cat#: X23-11-ZQ118) Lc3Cer (d18:1/8:0) (Cat#: X23-11-ZQ131) Lc4Cer (d18:1/12:0) (Cat#: X23-11-ZQ146) Sialyl-Lc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ162) Lewis a Cer (d18:1/16:0) (Cat#: X23-11-ZQ175) nLc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ190)
Cyclodextrin
Methyl-γ-cyclodextrin (DS 12) (Cat#: X23-11-YM119) Carboxymethyl-ɑ-cyclodextrin sodium salt (Cat#: X23-11-B003) Carboxymethyl-γ-cyclodextrin sodium salt (Cat#: X23-11-B004) Succinyl-ɑ-cyclodextrin (Cat#: X23-11-B005) Succinyl-γ-cyclodextrin (Cat#: X23-11-B006) ɑ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B007) β-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B008) γ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B009)
Dextran
Lysine-dextran, MW 4 kDa (Cat#: X22-09-ZQ273) Phenyl-dextran, MW 150 kDa (Cat#: X22-09-ZQ279) FITC-Q-dextran, MW 10 kDa (Cat#: X22-09-ZQ280) FITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ283) TRITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ287) FITC-dextran sulfate, MW 10 kDa (Cat#: X22-09-ZQ291) Dextran amine, MW 20 kDa (Cat#: X22-09-ZQ377) TRITC-dextran, MW 40 kDa (Cat#: X22-09-ZQ383) Biotin-dextran-FITC, MW 20 kDa (Cat#: X22-09-ZQ389)
Online Inquiry

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Important Links

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0